Please assess the completion status of the following clinical trial:

Trial Title: Gardasil Vaccination in Post Stem Cell Transplant Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Female stem cell transplant recipient at least 90 days post stem cell transplant~OR~Female stem cell transplant recipient at least 90 days post HSCT and on immunosuppression~OR~The matched female stem cell transplant donor for an included stem cell transplant recipient~OR~Healthy female subject~Age greater than or equal to 18 years and less than or equal to 50 years~EXCLUSION CRITERIA:~Vaccine Recipient:~Obvious HPV condyloma or obvious severe dysplasia (greater than or equal to CIN II) warranting treatment~History of severe adverse reaction to any components (yeast, eggs, monosodium glutamate or neomycin) of the quadrivalent HPV vaccine.~Untreated or persistent life-threatening infections not controlled by current treatment~Uncontrolled chronic GVHD i.e. highly active eGVHD requiring immediate intervention~Pregnant or breast feeding or unwilling to be abstinent or practice effective contraception during the study period (note: patients who have been rendered infertile with total body irradiation are eligible)~Enrollment in another vaccine clinical trial during the study period~Enrollment of healthy volunteer in a drug clinical trial during the study period~Inability to comprehend the investigational nature of the study and provide informed consent\<TAB\>~Prior Gardasil or other HPV vaccination~Persistent or recurrent malignancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: ACTIVE_COMPARATOR): Female subjects post stem cell transplant on no systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
- Cohort 2 (Type: ACTIVE_COMPARATOR): Female subjects post stem cell transplant with chronic GVHD requiring systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
- Cohort 3 (Type: ACTIVE_COMPARATOR): Healthy normal female volunteers. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).